Black Health
Vitamin K antagonist (oral anticoagulant) Atrial fibrillation DVT/PE Mechanical heart valves Antiphospholipid syndrome

Warfarin (Coumadin, Jantoven) and Black patients

Brand names: Coumadin, Jantoven

Last reviewed: Sources checked:

What Warfarin does

Warfarin prevents clotting by blocking the liver's production of vitamin-K-dependent clotting factors (II, VII, IX, X). It has been the mainstay oral anticoagulant since the 1950s. Dosing is challenging because of variable patient response, many food and drug interactions, and the need for regular INR blood tests.

What the evidence says for Black patients

Warfarin dosing has one of the largest race-specific evidence bases in all of pharmacology, rooted in pharmacogenomics. The key points:

  • Two genes dominate warfarin metabolism: CYP2C9 (enzyme that clears warfarin) and VKORC1 (vitamin K recycling target). Allele frequencies differ substantially by ancestry.
  • CYP2C9 variants (*5, *6, *8, *11) that reduce clearance are more common in African ancestry populations but are not captured by the standard clinical panel (*2, *3) validated in European cohorts. Limdi et al. (Blood 2008;112:1013–9, PMID 18523153) and Perera et al. (Lancet 2013;382:790–6, PMID 23755828) showed that including African-specific variants dramatically improves dose prediction in Black patients.
  • The IWPC dosing algorithm and the original FDA-label dosing tables were calibrated largely on European-ancestry cohorts and systematically over-anticoagulate Black patients — leading to higher rates of time above therapeutic range and bleeding complications. This is one of the clearest examples in medicine of genomic algorithm bias harming Black patients.
  • When warfarin must be used (e.g., mechanical mitral valve), Black patients benefit from pharmacogenomic-guided dosing that includes African-specific CYP2C9 variants — Gage et al. GIFT trial (JAMA 2017;318:1115–24, PMID 28973620) supports PGx dosing as superior to clinical algorithms alone.

Where a direct-acting oral anticoagulant (apixaban, rivaroxaban) is appropriate, it is typically preferred for Black patients with atrial fibrillation for this reason alone — no INR monitoring, no race-calibrated algorithm, no dietary interaction with greens.

Common alternatives

For atrial fibrillation and DVT/PE, apixaban (Eliquis) and rivaroxaban (Xarelto) are the main alternatives. For mechanical valves, warfarin remains the only evidence-based oral option.

Side effects

  • Major bleeding — intracranial, GI
  • Minor bleeding — epistaxis, bruising, gum bleeding
  • Warfarin-induced skin necrosis (rare, early)
  • Teratogenic — do not use in pregnancy except mechanical valves
  • Purple toe syndrome (rare)

Factors that affect adherence

Consistent INR monitoring is the foundation. Black patients should ask their prescriber whether African-specific CYP2C9 variants were considered in dosing, especially if INR has been unstable. Generic warfarin costs pennies; the clinic visits and lab draws are the real cost — point-of-care INR machines and mail-in test strips can ease access.

Questions to ask your doctor

Bring this list to your next appointment.

  • Am I a candidate for a DOAC (apixaban or rivaroxaban) instead of warfarin?
  • If I have to stay on warfarin, has my dosing algorithm accounted for African-ancestry CYP2C9 variants?
  • What's my INR goal range?
  • What do I do if I miss a dose, or if I start an antibiotic?

References

  1. Limdi NA, McGwin G, Goldstein JA, et al. Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Blood. 2008;112:1013–1019. PMID 18523153.
  2. Perera MA, Cavallari LH, Limdi NA, et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study. Lancet. 2013;382:790–796. PMID 23755828.
  3. Gage BF, Bass AR, Lin H, et al. Effect of genotype-guided warfarin dosing on clinical events and anticoagulation control among patients undergoing hip or knee arthroplasty (GIFT). JAMA. 2017;318:1115–1124. PMID 28973620.
  4. U.S. Food and Drug Administration. Coumadin (warfarin sodium) label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/009218s118lbl.pdf

Medical disclaimer

This page is patient education, not prescribing guidance. It summarizes the published evidence about how this medication has been studied in Black patients — it is not a substitute for the judgment of your personal clinician. Never start, stop, or change a prescription based on something you read here. If you have questions about your medication, call your prescriber or pharmacist. For emergencies, call 911.

Read our editorial standards for how we source, review, and update these pages.